Previous close | 2.4000 |
Open | 2.4000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 600.00 |
Expiry date | 2024-11-15 |
Day's range | 2.4000 - 2.4000 |
Contract range | N/A |
Volume | |
Open interest | 26 |
On Friday, Eli Lilly And Co (NYSE:LLY) released detailed results from the SURMOUNT-OSA phase 3 trials evaluating tirzepatide injection (10 mg or 15 mg) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy. In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacy and treatment-regimen estimands and demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI)
Eli Lilly is seeking FDA approval to expand the uses for its weight-loss drug Zepbound to include sleep apnea.
Apple is charged by the European Union for failing to comply with the Digital Markets Act, while separately, a report says the iPhone maker is talking with Meta Platforms about an artificial-intelligence partnership. Trump Media rises as it expects proceeds of nearly $70 million from the exercise of warrants last week.